These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 29110275

  • 1. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA, Pai RK, Shuai Y, Ramalingam L, Jones HL, Pingpank JF, Ahrendt SS, Holtzman MP, Zureikat AH, Zeh HJ, Bartlett DL.
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [Abstract] [Full Text] [Related]

  • 2. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Horvath P, Yurttas C, Birk P, Struller F, Königsrainer A.
    Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
    [Abstract] [Full Text] [Related]

  • 3. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M.
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [Abstract] [Full Text] [Related]

  • 4. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
    Beane JD, Wilson GC, Sutton JM, Shuai Y, Ramalingam L, Jones HL, Pingpank JF, Holtzman MP, Zureikat AJ, Ahrendt SA, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M.
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [Abstract] [Full Text] [Related]

  • 7. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
    Baratti D, Kusamura S, Milione M, Pietrantonio F, Caporale M, Guaglio M, Deraco M.
    Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S, Barretta F, Yonemura Y, Sugarbaker PH, Moran BJ, Levine EA, Goere D, Baratti D, Nizri E, Morris DL, Glehen O, Sardi A, Barrios P, Quénet F, Villeneuve L, Gómez-Portilla A, de Hingh I, Ceelen W, Pelz JOW, Piso P, González-Moreno S, Van Der Speeten K, Deraco M, Peritoneal Surface Oncology Group International (PSOGI) and the French National Registry of Rare Peritoneal Surface Malignancies (RENAPE).
    JAMA Surg; 2021 Mar 01; 156(3):e206363. PubMed ID: 33502455
    [Abstract] [Full Text] [Related]

  • 10. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.
    Eur J Surg Oncol; 2015 Mar 01; 41(3):396-9. PubMed ID: 25216980
    [Abstract] [Full Text] [Related]

  • 11. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB, Ma R, Ji ZH, Lin YL, Zhang J, Yang ZR, Chen LF, Yan FC, Li Y.
    Eur J Surg Oncol; 2020 Apr 01; 46(4 Pt A):600-606. PubMed ID: 31973925
    [Abstract] [Full Text] [Related]

  • 12. Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.
    Bhatt A, Mishra S, Prabhu R, Ramaswamy V, George A, Bhandare S, Shah M, Mehta S.
    Eur J Surg Oncol; 2018 Jul 01; 44(7):1105-1111. PubMed ID: 29685759
    [Abstract] [Full Text] [Related]

  • 13. Curative Surgical Resection as a Component of Multimodality Therapy for Peritoneal Metastases from Goblet Cell Carcinoids.
    Radomski M, Pai RK, Shuai Y, Ramalingam L, Jones H, Holtzman MP, Ahrendt SA, Pingpank JF, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2016 Dec 01; 23(13):4338-4343. PubMed ID: 27401448
    [Abstract] [Full Text] [Related]

  • 14. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
    Di Fabio F, Aston W, Mohamed F, Chandrakumaran K, Cecil T, Moran B.
    Colorectal Dis; 2015 Aug 01; 17(8):698-703. PubMed ID: 25704482
    [Abstract] [Full Text] [Related]

  • 15. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
    Solomon D, Bekhor E, Leigh N, Maniar YM, Totin L, Hofstedt M, Aycart SN, Carr J, Ballentine S, Magge DR, Golas BJ, Pai RK, Polydorides AD, Bartlett DL, Labow DM, Choudry HA, Sarpel U.
    Ann Surg Oncol; 2020 Jan 01; 27(1):147-153. PubMed ID: 31385130
    [Abstract] [Full Text] [Related]

  • 16. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
    Bignell MB, Mehta AM, Alves S, Chandrakumaran K, Dayal SP, Mohamed F, Cecil TD, Moran BJ.
    Colorectal Dis; 2018 Aug 01; 20(8):704-710. PubMed ID: 29502336
    [Abstract] [Full Text] [Related]

  • 17. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.
    Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.
    Eur J Surg Oncol; 2014 May 01; 40(5):515-520. PubMed ID: 24462284
    [Abstract] [Full Text] [Related]

  • 18. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S, Baratti D, Hutanu I, Gavazzi C, Morelli D, Iusco DR, Grassi A, Bonomi S, Virzì S, Haeusler E, Deraco M.
    Eur J Surg Oncol; 2015 Aug 01; 41(8):1097-105. PubMed ID: 26026742
    [Abstract] [Full Text] [Related]

  • 19. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ, Xia A, Zhai XC, Chen F, Xu HB.
    Zhonghua Zhong Liu Za Zhi; 2019 Sep 23; 41(9):698-702. PubMed ID: 31550861
    [Abstract] [Full Text] [Related]

  • 20. Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes.
    Baratti D, Milito P, Kusamura S, Martin Roman L, Guaglio M, Deraco M.
    Eur J Surg Oncol; 2022 Jul 23; 48(7):1590-1597. PubMed ID: 35090796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.